EMA Recommends Extension of Indications for Durvalumab to Include Treatment of Patients with Resectable NSCLC at High Risk of Recurrence By Ogkologos - March 28, 2025 702 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns neoadjuvant and adjuvant treatment of patients with resectable non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic MOST POPULAR Zilovertamab Vedotin Is Safe and Demonstrates Activity In Heavily Pretreated Patients... October 18, 2021 FDA Approves Pembrolizumab with Chemotherapy for Primary Advanced or Recurrent Endometrial... July 24, 2024 New on NCI’s Websites for January 2020 January 2, 2020 Radiation Treatment Delivery Improved Using a Visualization of the Invisible Radiation... January 21, 2021 Load more HOT NEWS Mosunetuzumab Plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed... Association of BRCA1 and BRCA2 Pathogenic Variants with Increased Risk of... Fosnetupitant Is Valuable in the Prophylaxis of Acute, Delayed, and Beyond... FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for...
